Pipeline

Platform

Modality

Indication

Payload

Discovery

Preclinical Development

IND-Enabling

Phase 1

Intratumoral Delivery

Self-replicating mRNA

STX-001

Indication

Melanoma, TNBC, and other solid tumors

Payload

IL-12

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-001

STX-002

Indication

Undisclosed

Payload

Undisclosed

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-002

Systemic Delivery

Self-replicating mRNA circuit for intravenous delivery (non-liver)

STX-003

Indication

NSCLC and other solid tumors

Payload

IL-12

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-003

STX-006

Indication

Undisclosed

Payload

Undisclosed

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-006

Immune Cell Engineering

Circular RNA circuit

STX-004

Indication

Hematological malignancies

Payload

CAR

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-004

STX-005

Indication

Hematological malignancies

Payload

CAR

Discovery

Preclinical Development

IND-Enabling

Phase 1

STX-005

Strand's technology is therapeutic-area and mRNA modality agnostic; therapeutic proteins are encoded onto modified, self-replicating, or circular mRNA backbones which in turn are programmed with cell-specific sensors and circuits

mRNA: messenger RNA; TNBC: triple negative breast cancer; NSCLC: non-small cell lung cancer; IL-12: interleukin 12; CAR: chimeric antigen receptor